NCT00629642View on ClinicalTrials.gov

Clinical Study of Solifenacin Succinate in Patients With Bladder Symptoms Due to Spinal Cord Injury or Multiple Sclerosis

PHASE4CompletedINTERVENTIONAL
Enrollment

249

Participants

Timeline

Start Date

March 14, 2008

Primary Completion Date

January 28, 2011

Study Completion Date

January 28, 2011

Conditions
Multiple SclerosisNeurogenic BladderSpinal Cord Diseases
Interventions
DRUG

Solifenacin Succinate

Oral, 10mg

DRUG

Solifenacin Succinate

Oral, 5mg

DRUG

Oxybutynin Hydrochloride

Oral, 15mg

DRUG

Placebo

Oral

Trial Locations (39)

190089

Saint Petersburg

196084

Saint Petersburg

Unknown

Brisbane

Melbourne

Perth

Randwick

Antwerp

Esneux

Fraiture-en-Condroz

Ghent

Leuven

Melsbroek

Brno

České Budějovice

Prague

Caen

Garches

Paris

Ploemeur

Berlin

Hagenow

Heidelberg

Kiel

Nyíregyháza

Sopron

Szeged

Florence

Milan

Rome

Torino

Apeldoorn

Eindhoven

Nijmegen

Sant Joan d'Alacant

Badalona

Getafe

A Coruña

Cardiff

Newcastle upon Tyne

Sponsors
All Listed Sponsors
lead

Astellas Pharma Inc

INDUSTRY